**Specification table**TableSubject area*Medicine*More specific subject area*Metabolism*Type of data*Figure*How the data were acquired*Weighing mice body weights and food consumption weekly using a suitable scale and all graphs were obtained using GraphPad Prism 5.*Data format*Analyzed*Experimental factors*Mice were treated with weekly intra-peritoneal injections of either normal saline or PG545 for 12 weeks.*Experimental features*Mice body weights and food intake were assessed weekly and data presented in the attached figure.*Data source location*The Rappaport Faculty of Medicine, Technion, Israel institute of technology, Haifa, Israel.*Data accessibility*The data are in this article.*Related research articleShekh-Muhammad R, Abu-Saleh N, Kinaneh S, Agbaria M, Sabo E, Grajeda-Iglesias C, Volkova N, Hamoud S: Heparanase inhibition attenuates atherosclerosis progression and liver steatosis in E~**0**~ mice (in press). *Atherosclerosis* 2018 [@bib1].

**Value of data**●Data from a well-designed research, dealing with a common health concern with poor understanding and lacks efficient treatment options.●The data provide a new insight into investigating and offering a possible therapeutic option for a common health concern.●Treating weight gain or obesity is of therapeutic value in controlling several diseases, such as diabetes mellitus, hypertension, hyperlipidemia and many others.●The data provide a basis for further research towards unveiling underlying mechanisms of obesity, dyslipidemias and related morbidity, and affording treatment options for such a common phenomenon.

1. Data {#s0005}
=======

The data present the weekly measurements of the average mice body weights (in grams, [Fig. 1](#f0005){ref-type="fig"}A), weekly food intake (per mouse in grams, [Fig. 1](#f0005){ref-type="fig"}B) and mean food intake throughout the study period (per mouse in grams, [Fig. 1](#f0005){ref-type="fig"}C). Values are presented as mean ± SEM.Fig. 1Effect of PG545 on mice body weight and food intake throughout the study in E~0~ mice**.** Weekly measurements of mice body weight (grams, A), food intake (per mouse in grams, B) and mean food intake throughout the study (grams/mouse, C). Values are presented as mean ± SEM. \* Compared to control group. \# Compared to PG545 low-dose group, \*/\# *p* \< 0.05, \*\*/\#\# *P* \< 0.01, \*\*\*/\#\#\# *P* \< 0.001.Fig. 1

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Animal studies {#s0015}
-------------------

Male E~0~ mice, 12--13-week-old (Body weight \~30 g/mouse at baseline) were bred and housed in a pathogen-free environment and placed on high fat diet (HFD). The study was conducted according to the National Institutes of Health guideline and was approved by the Technion Ethics Committee (Ethics no. IL1090717).

2.2. Experimental design {#s0020}
------------------------

Sham-Control group (*n* = 6) received weekly normal saline injections (0.1 ml/mouse, intraperitoneally -- IP). Treatment groups (*n* = 7 in each) were treated with PG545 at either 0.2 mg/mouse (6.4 mg/kg − the low dose group) or 0.4 mg/mouse (13.3 mg/kg − the high dose group) administered IP once a week for 12 weeks [@bib2], [@bib3].

Mice body weights and food intake were assessed weekly. Data were analyzed and conducted using GraphPad Prism version 5.03 (GraphPad Software, Inc. CA, 92037 USA). A value of *p* \< 0.05 was considered statistically significant. Data are presented as mean ± SEM.
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